Back to top
more

Voyager Therapeutics (VYGR)

(Delayed Data from NSDQ)

$7.82 USD

7.82
495,064

+0.05 (0.64%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $7.80 -0.02 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for VYGR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Voyager Therapeutics, Inc. [VYGR]

Reports for Purchase

Showing records 61 - 80 ( 142 total )

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 61

02/14/2020

Industry Report

Pages: 7

Runners up Is the New Killing It, and Other Tidbits

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 62

02/07/2020

Daily Note

Pages: 9

Let’s Caucus, or Never Again; In an Otherwise Ho-Hum Earnings Week

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 63

01/09/2020

Daily Note

Pages: 18

2020 Catalyst Calendar and Top Picks Across Mid, Small, and Micro Caps

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 50.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 64

11/07/2019

Company Report

Pages: 10

3Q19 Update Reflects a Pushout of the HD Program

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 65

11/06/2019

Company Report

Pages: 15

Assuming Coverage: With 2020 Catalysts, Like the Setup Into New Year

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 66

09/04/2019

Industry Report

Pages: 13

2H19 Value Drivers Within Our Coverage Universe

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 50.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 67

08/12/2019

Company Report

Pages: 10

1H19 Recap: Lull in Near Term Clinical Milestones to Be Punctured With HD IND Submission by YE19

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 68

08/12/2019

Company Report

Pages: 9

2Q19; Looking Ahead to Huntington’s Disease IND Filing Late This Year

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 69

07/01/2019

Industry Report

Pages: 49

Key Take-Aways from HD KOL Dinner

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 100.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 70

06/18/2019

Company Report

Pages: 10

Reading Tea Leaves Post Sanofi Collaboration Restructuring

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 71

06/18/2019

Company Report

Pages: 8

Adding Huntington’s to Valuation on Pipeline Restructuring

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 72

06/18/2019

Daily Note

Pages: 6

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 73

05/08/2019

Company Report

Pages: 12

1Q19 Financials; Increasing PT on Positive AAN and ASGCT Updates

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 74

05/08/2019

Company Report

Pages: 10

Execution the Persistent Theme During 1Q19; Moving Target to $26

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 75

05/06/2019

Daily Note

Pages: 11

Narrowing Inclusion Criteria Increases Odds of Pivotal Success; Thoughts Post AAN Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 76

04/18/2019

Industry Report

Pages: 10

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 77

03/04/2019

Company Report

Pages: 11

A CNS Focused Gene Therapy With Plenty of Headroom

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 78

02/28/2019

Company Report

Pages: 6

Partnerships back VYGR Voyage in Parkinson’s and other Indications

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 79

02/28/2019

Daily Note

Pages: 10

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 80

02/25/2019

Company Report

Pages: 13

$27M EV Does Little Justice to Continued Execution on the BD Front; Modest Upward Revision to Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 50.00

Research Provided by a Third Party